Gold prices slip slightly after recent gains; U.S. data eyed
Shaw Daren, a director at Ensign Group, Inc. (NASDAQ:ENSG), recently sold 2,000 shares of the company’s common stock. The transaction, executed on February 14, 2025, was carried out at a price of $129.66 per share, totaling approximately $259,320. The healthcare company, currently valued at $7.29 billion, maintains strong financial health according to InvestingPro analysis. Following this sale, Daren holds 26,325 shares in the company. The transaction was part of a pre-established Rule 10b5-1 trading plan adopted on May 6, 2024. With a PEG ratio of 0.61 and historically low price volatility, InvestingPro data reveals 8 additional key insights about ENSG’s valuation and growth prospects. Access the comprehensive Pro Research Report for deeper analysis of this healthcare provider’s financial position and market outlook.
In other recent news, The Ensign Group Inc. has been the subject of multiple analyst upgrades. Stephens analyst Scott Fidel raised the company’s stock target to $160, maintaining an Overweight rating. Fidel emphasized the company’s consistent mid-teens compound annual growth rates in revenue and adjusted earnings per share, and its strategy to expand through mergers and acquisitions.
Simultaneously, Macquarie analyst Tao Qiu lifted the stock target to $166, keeping an Outperform rating. Qiu highlighted the accelerated acquisition activity and projected revenue growth between 12.5% and 15.0% for 2025, surpassing consensus estimates.
In addition, UBS initiated coverage on The Ensign Group with a Buy rating and a price target of $175.00. UBS acknowledged the company’s ability to acquire and revitalize underperforming facilities, and its potential to capitalize on the fragmented skilled nursing facility industry’s challenges.
These recent developments underscore the analysts’ confidence in The Ensign Group’s growth strategy and robust financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.